FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1607215679> ?p ?o ?g. }

• W1607215679 endingPage "2240" @default.
• W1607215679 startingPage "2229" @default.
• W1607215679 abstract "Adjuvant endocrine therapy (ET) is indicated in patients with steroid hormone receptor (HR)-positive breast cancer. The aim of this study was to evaluate the quality of HR determination and adjuvant endocrine treatment of breast cancer patients in a large cohort of more than 7000 women by analyzing data from a population-based regional cancer registry. Data from the Clinical Cancer Registry Regensburg (Bavaria, Germany) were analyzed. Female patients with primary, nonmetastatic invasive breast cancer who were diagnosed between 2000 and 2012 (n = 7421) were included. HR-status was available in 97.4 % (n = 7229) of the patients. This data set (n = 7229) was used for subsequent statistical analyses. Since 2009, almost a complete rate of 99.6 % of analyzed HR-status was achieved. In sum, 85.8 % of the patients (n = 6199) were HR-positive, whereas 14.2 % (n = 1030) were HR-negative. Overall, 85.3 % (n = 5285) of HR-positive patients received ET either alone or in combination with chemotherapy (CHT) and/or trastuzumab. The majority of premenopausal patients received CHT plus ET (716 patients, 52.3 %). In postmenopausal patients, the most frequent systemic therapy was ET alone (2670 patients, 55.3 %). Best overall survival (OS) was found in HER2-/HR-positive patients receiving CHT plus ET plus trastuzumab (7-year OS rate of 97.2 % in premenopausal patients versus 86.9 % in postmenopausal patients). Premenopausal patients had a reduced benefit from additional CHT than postmenopausal patients. Premenopausal patients receiving only ET had a 7-year OS rate of 95.3 % compared to 92.7 % of patients receiving CHT plus ET. In contrast, postmenopausal patients treated with CHT plus ET had a 7-year OS rate of 84.0 % in comparison with those patients receiving only ET with a 7-year OS rate of 81.7 %. Analysis of HR in patients with early breast cancer achieved a very high quality in recent years. The vast majority of HR-positive patients received ET, and this guideline-adherent use improved OS. Inverse effects of the CHT plus ET combination in premenopausal versus postmenopausal patients and a still existing minority of patients not receiving guideline-adherent treatment should be further investigated in future studies." @default.
• W1607215679 created "2016-06-24" @default.
• W1607215679 creator A5016291443 @default.
• W1607215679 creator A5031026217 @default.
• W1607215679 creator A5036428735 @default.
• W1607215679 creator A5037530630 @default.
• W1607215679 creator A5061837315 @default.
• W1607215679 creator A5072449661 @default.
• W1607215679 creator A5072723216 @default.
• W1607215679 creator A5082116571 @default.
• W1607215679 creator A5082458211 @default.
• W1607215679 creator A5087151081 @default.
• W1607215679 date "2015-08-08" @default.
• W1607215679 modified "2023-09-24" @default.
• W1607215679 title "Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry" @default.
• W1607215679 cites W110029000 @default.
• W1607215679 cites W1453600927 @default.
• W1607215679 cites W1491616134 @default.
• W1607215679 cites W1531964529 @default.
• W1607215679 cites W1893057588 @default.
• W1607215679 cites W1961026612 @default.
• W1607215679 cites W1970317488 @default.
• W1607215679 cites W1977295091 @default.
• W1607215679 cites W2015473392 @default.
• W1607215679 cites W2038989281 @default.
• W1607215679 cites W2041616813 @default.
• W1607215679 cites W2044702943 @default.
• W1607215679 cites W2045064272 @default.
• W1607215679 cites W2048364560 @default.
• W1607215679 cites W2058871711 @default.
• W1607215679 cites W2087476508 @default.
• W1607215679 cites W2101881391 @default.
• W1607215679 cites W2118696602 @default.
• W1607215679 cites W2118728607 @default.
• W1607215679 cites W2123221226 @default.
• W1607215679 cites W2137853125 @default.
• W1607215679 cites W2142753818 @default.
• W1607215679 cites W2143295270 @default.
• W1607215679 cites W2145166201 @default.
• W1607215679 cites W2151396148 @default.
• W1607215679 cites W2161311102 @default.
• W1607215679 cites W2161977537 @default.
• W1607215679 cites W2163688875 @default.
• W1607215679 cites W2333741771 @default.
• W1607215679 cites W2333998007 @default.
• W1607215679 cites W2340386540 @default.
• W1607215679 cites W2435615795 @default.
• W1607215679 doi "https://doi.org/10.1007/s00432-015-2025-z" @default.
• W1607215679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4630246" @default.
• W1607215679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26253629" @default.
• W1607215679 hasPublicationYear "2015" @default.
• W1607215679 type Work @default.
• W1607215679 sameAs 1607215679 @default.
• W1607215679 citedByCount "11" @default.
• W1607215679 countsByYear W16072156792015 @default.
• W1607215679 countsByYear W16072156792016 @default.
• W1607215679 countsByYear W16072156792017 @default.
• W1607215679 countsByYear W16072156792020 @default.
• W1607215679 countsByYear W16072156792021 @default.
• W1607215679 crossrefType "journal-article" @default.
• W1607215679 hasAuthorship W1607215679A5016291443 @default.
• W1607215679 hasAuthorship W1607215679A5031026217 @default.
• W1607215679 hasAuthorship W1607215679A5036428735 @default.
• W1607215679 hasAuthorship W1607215679A5037530630 @default.
• W1607215679 hasAuthorship W1607215679A5061837315 @default.
• W1607215679 hasAuthorship W1607215679A5072449661 @default.
• W1607215679 hasAuthorship W1607215679A5072723216 @default.
• W1607215679 hasAuthorship W1607215679A5082116571 @default.
• W1607215679 hasAuthorship W1607215679A5082458211 @default.
• W1607215679 hasAuthorship W1607215679A5087151081 @default.
• W1607215679 hasBestOaLocation W16072156791 @default.
• W1607215679 hasConcept C121608353 @default.
• W1607215679 hasConcept C126322002 @default.
• W1607215679 hasConcept C143998085 @default.
• W1607215679 hasConcept C2776694085 @default.
• W1607215679 hasConcept C2778527826 @default.
• W1607215679 hasConcept C2779786085 @default.
• W1607215679 hasConcept C2908647359 @default.
• W1607215679 hasConcept C29456083 @default.
• W1607215679 hasConcept C46699223 @default.
• W1607215679 hasConcept C530470458 @default.
• W1607215679 hasConcept C71315377 @default.
• W1607215679 hasConcept C71924100 @default.
• W1607215679 hasConcept C72563966 @default.
• W1607215679 hasConcept C99454951 @default.
• W1607215679 hasConceptScore W1607215679C121608353 @default.
• W1607215679 hasConceptScore W1607215679C126322002 @default.
• W1607215679 hasConceptScore W1607215679C143998085 @default.
• W1607215679 hasConceptScore W1607215679C2776694085 @default.
• W1607215679 hasConceptScore W1607215679C2778527826 @default.
• W1607215679 hasConceptScore W1607215679C2779786085 @default.
• W1607215679 hasConceptScore W1607215679C2908647359 @default.
• W1607215679 hasConceptScore W1607215679C29456083 @default.
• W1607215679 hasConceptScore W1607215679C46699223 @default.
• W1607215679 hasConceptScore W1607215679C530470458 @default.
• W1607215679 hasConceptScore W1607215679C71315377 @default.
• W1607215679 hasConceptScore W1607215679C71924100 @default.
• W1607215679 hasConceptScore W1607215679C72563966 @default.

• next